Associate Professor, Internal Medicine, Ohio State University College of Medicine
Oncology
Dr. Kari L. Kendra, MD
|
|
Give Review
Kari L. Kendra practices Oncology. She researched medicine at Rush Medical College. She has 1 awards "CMS Meaningful Use Stage 1 Certification". Kari Kendra is also published. She has 14 publications published. The lastest publication: "Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor bearing hosts by ibrutinib treatment.' Kari Kendra accepts Medicare payments and is registered with Medicare.gov.
Publications
- Myeloid-derived suppressor Cells express Bruton's tyrosine kinase and can be depleted in tumor bearing hosts by ibrutinib treatment.
- A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic Melanoma.
- Cotreatment of hairy cell Leukemia and melanoma with the BRAF inhibitor dabrafenib.
- A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors.
- Focal takotsubo cardiomyopathy with high-dose interleukin-2 therapy for Malignant melanoma.
- Radiation necrosis mimicking rapid intracranial progression of Melanoma metastasis in two patients treated with vemurafenib.
- A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal Cell carcinoma and melanoma.
- A Phase I Trial of Bortezomib and Interferon-α-2b in Metastatic Melanoma.
- Case of Sorafenib-Induced Thyroid Storm.
- gp100 peptide vaccine and interleukin-2 in patients with advanced Melanoma.
- A pilot study of bevacizumab and interferon-α2b in ocular Melanoma.
- Stereotactic radiosurgery alone for patients with 1-4 radioresistant Brain metastases.
- Stereotactic radiosurgery with or without whole Brain radiotherapy for patients with a single radioresistant Brain metastasis.
Schools
Rush Medical College Of Rush University
University Of Wi Hospital and Cli
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Wisconsin -
Rush Medical College
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1417964958 | |
| NPPES Provider LastName | KENDRA | |
| NPPES Provider FirstName | KARI | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 226.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417964958 |
| Last Name Of The Provider | KENDRA |
| First Name Of The Provider | KARI |
| View All |
Similar Doctors
|
Dr. Tarek A. Chidiac, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John P. Kuebler, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Manisha H. Shah, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jeanna L. Knoble, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George S. Lewandowski, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. R Bryan Butler, MD |
|
Dr. Maura L. Gillison, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|